Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study is a two-arm prospective 1:1 randomised controlled trial comparing the proportion
of patients between:
Group 1: vorinostat/hydroxychloroquine/maraviroc (VHM) co-administered with anti-retroviral
therapy (ART) Group 2: ART only who are able to maintain HIV RNA < 50 copies/ml following
treatment interruption. Subjects will be recruited from RV254/SEARCH 010, an acute HIV
infection cohort conducted by the Thai Red Cross AIDS Research Centre in Bangkok, Thailand.
The study will run for a minimum of 34 weeks from screening.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
South East Asia Research Collaboration with Hawaii
Collaborators:
Cooper Human Systems The Thai Red Cross AIDS Research Centre